GB Sciences Signs Licensing Deal With «EndoPure« Life Sciences for 5 Percent Gross Sales Royalty & Sponsorship of First in Human Trial for Their Cannabinoid Based Parkinson’s Drug
As a part of their Exclusive Licensing Deal, “EndoPure” Life Sciences will finance and sponsor first in human clinical trials, which help to advance GB Sciences’ cannabinoid based products globally, mehr …
xn--gtsel-kva.de/content/94248/gb-sciences-signs-licensing-deal-with-endopure-life-sciences-for-5-percent-gross-sales-royalty-und-sponsorship-of-first-in-human-trial-for-their-cannabinoid-based-parkinsons-drug.html
Gb Sciences’ Novel Parkinson’s Disease Medication is Featured on Worldwide Business with Kathy Ireland
Tune in this Sunday, December 17th, 2023, at 5.30 p. m. ET on the Fox Business Network to learn about Gb Sciences’ cannabinoid based medicine for the treatment of Parkinson’s disease, mehr …
xn--gtsel-kva.de/content/80393/gb-sciences-novel-parkinsons-disease-medication-is-featured-on-worldwide-business-with-kathy-ireland.html
Pfizer und Biontech stellen COVID-19-Impfstoffdosen für Teilnehmer der Olympischen Spiele 2020 in Tokio zur Verfügung
Pfizer Inc. (NYSE: PFE) und Biontech SE (Nasdaq: BNTX) gaben heute die Unterzeichnung einer Absichtserklärung (Memorandum of Understanding, »MoU«) mit dem Internationalen Olympischen Komitee (IOC) bekannt. Die Unternehmen werden COVID-19-Impfstoffdosen zur Verfügung stellen, um die Impfung teilnehmender Athleten sowie ihrer Delegationen, mehr …
xn--gtsel-kva.de/content/21685/pfizer-und-biontech-stellen-covid-19-impfstoffdosen-fuer-teilnehmer-der-olympischen-spiele-2020-in-tokio-zur-verfuegung.html
Enterin and Their Collaborators at NIH Announce That Alpha-Synuclein, the Culprit in Parkinson's Disease, is Core and Central to Normal Immune Function
Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and metabolic diseases, announces the publication of a paper entitled “Alpha-synuclein, the culprit in Parkinson's Disease, is required for normal immune function.”, mehr …
xn--gtsel-kva.de/content/34405/enterin-and-their-collaborators-at-nih-announce-that-alpha-synuclein-the-culprit-in-parkinson-und-apos-s-disease-is-core-and-central-to-normal-immune-function.html
Enterin to Announce Top-Line Results From the Phase 2b Study for Parkinson’s Disease
Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and metabolic diseases, today announced that it will host a webinar to present top-line results from the Phase 2b (KARMET) study in patients with Parkinson’s disease on Thursday, Jan. 27 at 2:30 pm EST, mehr …
xn--gtsel-kva.de/content/35483/enterin-to-announce-top-line-results-from-the-phase-2b-study-for-parkinsons-disease.html
Breakthrough Innovation Forum, Bayer treibt bahnbrechende Innovationen in den Life Sciences voran
Das Unternehmen investiert in den kommenden 3 Jahren mehr als 1,3 Milliarden Euro in seine Impact Investment Einheit Leaps by Bayer, mehr …
xn--gtsel-kva.de/content/40420/breakthrough-innovation-forum-bayer-treibt-bahnbrechende-innovationen-in-den-life-sciences-voran.html
Novo Nordisk to Expand R & D Presence in Greater Boston Area
Novo Nordisk just announced plans to expand its research and development (R & D) presence in the greater Boston metro area, creating one of its largest R & D hubs outside of Denmark, mehr …
xn--gtsel-kva.de/content/60535/novo-nordisk-to-expand-r-und-d-presence-in-greater-boston-area.html
Select Greater Philadelphia Council, Stories From Our Region
»StrongRoom« AI’s Expansion into Greater Philadelphia Shows Strength of Region’s Business Community Australian company »StrongRoom« AI recently opened its first U. S. location in Greater Philadelphia, mehr …
xn--gtsel-kva.de/content/90622/select-greater-philadelphia-council-stories-from-our-region.html
